A5046320723- Health Systems, Economic Evaluations, Quality of Life
- Public Health in Brazil
- Economic and Financial Impacts of Cancer
- Pharmaceutical Economics and Policy
- Cancer Genomics and Diagnostics
- Women's cancer prevention and management
- Global Cancer Incidence and Screening
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Prostate Cancer Treatment and Research
- Healthcare during COVID-19 Pandemic
- Colorectal Cancer Treatments and Studies
- Pain Management and Opioid Use
- Pediatric Pain Management Techniques
- Maternal and Neonatal Healthcare
- COVID-19 and healthcare impacts
- HER2/EGFR in Cancer Research
- Health, Nursing, Elderly Care
- Advanced Radiotherapy Techniques
- Colorectal Cancer Screening and Detection
- Advanced Breast Cancer Therapies
- Head and Neck Cancer Studies
- Molecular Biology Techniques and Applications
- Cutaneous Melanoma Detection and Management
- BRCA gene mutations in cancer
Coordenação de Aperfeicoamento de Pessoal de Nível Superior
2023-2024
Fleury S.A. (Brazil)
2022
Centro de Pesquisas Oncológicas
2021
Hospital Mãe de Deus
2011-2020
Broadlawns Medical Center
2006
Hospital de Clínicas de Porto Alegre
1999
Universidade Federal do Rio Grande do Sul
1999
Radical new possibilities of improved treatment cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use focused highly personalized treatments. However, across regions globally, many patients will continue to be denied benefits NGS as long some yawning gaps in implementation remain unattended. The challenges at regional national levels...
Tackling cancer is a major challenge right on the global level. Europe only tip of an iceberg around world. Prosperous developed countries share same problems besetting Europe-and and regions with fewer resources less propitious conditions are in many cases struggling often heroically against growing tide disease. This paper offers view these geographically wider, but essentially similar, challenges, prospects for barriers to better results this ceaseless battle. A series panels have been...
Objective: A cost-minimisation and budget impact analysis of erlotinib versus docetaxel or pemetrexed as second-line treatment for advanced non-small-cell lung cancer (NSCLC).Methods: Costs budgetary impacts were estimated from the perspective a Brazilian private healthcare payer, based on results BR.21 study pivotal trials pemetrexed. 126-day timeframe was evaluated, progression-free survival determined in BR.21. Delphi panel identified local practices associated costs Brazil. Other...
Background: The global burden of breast cancer (BC) is high, especially in advanced stages. CDK 4/6 inhibitors represent a paradigm shift the treatment BC HR+/HER2−, given clinically and statistically significant gain overall survival associated with this new class medications. Nevertheless, as an innovation, incorporation these drugs impacts healthcare budgets, requiring cost-effectiveness analyses for decision-making. aim study was to evaluate ribociclib plus letrozole compared palbociclib...
Abstract Background Adoption of molecular pathology in Brazil is currently very limited. Of note, there are no programs for training new pathologists the country; thus, documents compiling nationally applicable information on few. Methods A selected panel Brazilian experts fields related to were provided with a series relevant questions address prior multi-day conference. Within this conference, each narrative was discussed and edited by entire group, through numerous drafts rounds...
The development of therapies that restore or activate the host immune response - socalled "immuno-oncologic" therapy has improved survival some cancer patients harboring specific tumor types. These drugs, however, are very expensive which greatly limited their use and consequently reduced number who could likely benefit. Not to mention, proportion display a clinical benefit from is limited. Thus, health economics perspective, there pressing need identify treat those for whom given immuno-...
We present the case of a patient with urethral metastasis lung carcinoma germinative cell features.A White, 57-year old man underwent urologic assessment due to gross hematuria. Patient was being treated chemotherapy and radiotherapy during past 3 months primary brain metastasis. Urethrocistoscopy nuclear magnetic resonance imaging revealed stenosing mass invading bulbomembranous urethra. No other tumor found. Biopsy specimens, obtained from lung, urethra tumors, same neoplasia, definitive...
e18838 Background: In Brazil, cancer, in addition to being one of the main causes illness and death, represents highest public private healthcare expenses. Regardless population profile, direct costs cancer pose as a real threat health system's sustainability. The objective this study is analyze evolution use chemotherapy, targeted therapy, hormone therapy immunotherapy. Methods: Retrospective cohort consisted all plan beneficiaries diagnosed with who received pharmacological treatment last...
203 Background: Anti-EGFR treatment of RAS wild-type metastatic colorectal cancer (mCRC) in Latin America includes cetuximab or panitumumab, added to chemotherapy (cet+CT and pan+CT, respectively). Adverse event (AE) profiles for each regimen may influence the decision. This study aimed estimate associated financial impact AE management three countries: Argentina (AR), Brazil (BR) Panama (PA) from a healthcare payer perspective. Methods: We revised published Microsoft Excel-based economic...